The Situation
Guardant Health Inc (NASDAQ: GH) shares – a precision oncology biotech company engaged in cancer treatment – plunged after recent blood test failed to meet investor's expectations. As of 12:00 PM ET, Guardant shares dropped by 31.33%.
GH Stocks Plunged: Here's What Happened
12/16/2022
The Explanation
Guardant Health Inc officially went public on Oct 4, 2018, reaching an all-time high of $179.10 on Feb 12, 2021, with a price performance drop of just 2.81% overall. The company shares dropped to $28.41 as of press time, with a 71.76% year-to-date.
The company announced its blood test catching 83% of colorectal cancer cases. The tests were designed to screen for cancer, and although the company says this could unlock a $20 billion market, investors were disappointed with the results.
See the $GH chart performance here.
The Effect
Guardant Health Inc stocks reportedly dropped after its blood test results were released. The investors' reaction happened as some of them were afraid that the results were not good enough to gain approval and that it won't be the first choice when it comes to colorectal cancer screening.
Since investors can't know for sure if the test results are good enough to gain approval, it is more important to focus on Guardant's business.
See full $GH flow at: https://unusualwhales.com/stock/GH/flow-overview
Elon Musk has said he is back
5/24/2025 11:31 PMNvidia, NVDA, to launch cheaper Blackwell AI chip for China after US export curbs
5/24/2025 11:25 PMRay Dalio has said the risks from U.S. credit downgrade ‘are greater than the rating agencies are conveying’
5/23/2025 7:39 PMU.S. economy is experiencing ‘death by a thousand cuts’, Deutsche Bank has said
5/23/2025 7:37 PM
Stay Updated
Subscribe to our newsletter for the latest financial insights and news.
Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.